Abbas Mohammadipour

Abbas Mohammadipour

Auto-generated profile, based on publicly available information

Abbas Mohammadipour

Department of Anatomy and Cell Biology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

Research Focus & Metrics

Academic Career Length

10Years (2017-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 February 2022 in Cellular and Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SRSeyed Hamidreza Rastegar-Moghaddam
Seyed Hamidreza Rastegar-Moghaddam
AEAlireza Ebrahimzadeh-Bideskan
Alireza Ebrahimzadeh-Bideskan
SSSara Shahba
Sara Shahba
AMAmir mohammad Malvandi
Amir mohammad Malvandi
AMAbbas Mohammadipour
Abbas Mohammadipour

1 July 2017 in Experimental and Toxicologic Pathology
Verified
Journal Article
Closed access
AEAlireza Ebrahimzadeh-bideskan
Alireza Ebrahimzadeh-bideskan
AMAbbas Mohammadipour
Abbas Mohammadipour
AFAlireza Fazel
Alireza Fazel
HHHossein Haghir
Hossein Haghir
HRHoushang Rafatpanah
Houshang Rafatpanah
ARAliakbar Rajabzadeh
Aliakbar Rajabzadeh

3 March 2021 in Metabolic Brain Disease
Verified
Journal Article
Closed access
PDF file
MBMaryam Bigham
Maryam Bigham
AMAbbas Mohammadipour
Abbas Mohammadipour
MHMahmoud Hosseini
Mahmoud Hosseini
AMAmir Mohammad Malvandi
Amir Mohammad Malvandi
AEAlireza Ebrahimzadeh-Bideskan
Alireza Ebrahimzadeh-Bideskan

4 January 2023 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
VEVahid Ebrahimi
Vahid Ebrahimi
SRSeyed Hamidreza Rastegar-Moghaddam
Seyed Hamidreza Rastegar-Moghaddam
AMAbbas Mohammadipour
Abbas Mohammadipour

14 February 2022 in Molecular Neurobiology
Verified
Journal Article
Closed access
PDF file
SRSeyed Hamidreza Rastegar-Moghaddam
Seyed Hamidreza Rastegar-Moghaddam
AEAlireza Ebrahimzadeh-Bideskan
Alireza Ebrahimzadeh-Bideskan
SSSara Shahba
Sara Shahba
AMAmir mohammad Malvandi
Amir mohammad Malvandi
AMAbbas Mohammadipour
Abbas Mohammadipour

23 September 2022 in Molecular Medicine
Verified
Journal Article
Open access
PDF file
AMAmir mohammad Malvandi
Amir mohammad Malvandi
SRSeyed Hamidreza Rastegar-Moghaddam
Seyed Hamidreza Rastegar-Moghaddam
SESaeede Ebrahimzadeh-Bideskan
Saeede Ebrahimzadeh-Bideskan
Giovanni LombardiGiovanni Lombardi
Giovanni Lombardi
AEAlireza Ebrahimzadeh-Bideskan
Alireza Ebrahimzadeh-Bideskan
AMAbbas Mohammadipour
Abbas Mohammadipour
Spinal cord injury (SCI) is a devastating neurological state causing physical disability, psychological stress and financial burden. SCI global rate is estimated between 250,000 and 500,000 individuals every year, of which 60% of victims are young, healthy males between 15 and 35 years. A variety of pathological conditions such as neuroinflammation, mitochondrial dysfunction, apoptosis, glial scar formation, blood-spinal cord barrier disruption, and angiogenesis disruption occur after SCI leading to a limitation in recovery. MicroRNAs (miRs) are endogenous and non-coding RNAs consisting of 22 nucleotides that regulate 60% of all human genes and involve several normal physiological processes and pathological conditions. miR-21 is among the most highly expressed miRs and its expression has been shown to increase one day after SCI and this elevation is sustained up to 28 days after injury. Overexpression of miR-21 exerts many protective effects against SCI by inhibiting neuroinflammation, improving blood-spinal cord barrier function, regulating angiogenesis, and controlling glial scar formation. It also exhibits anti-apoptotic effects in SCI by down-regulating the expression of PTEN, Spry2, and PDCD4. This review provides a novel therapeutic perspective for miR-21 in SCI.